Angiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, Padua University Hospital, Padua, Italy.
General Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Internal Medicine, Padua University Hospital, Padua, Italy.
Clin Transl Sci. 2020 Nov;13(6):1108-1114. doi: 10.1111/cts.12907. Epub 2020 Oct 23.
Despite thromboprophylaxis, patients with coronavirus disease 2019 (COVID-19) exhibit hypercoagulability and higher venous thromboembolic risk, although its real incidence is still unknown. The aim of this study was to evaluate the incidence of venous thromboembolism (VTE) in patients with COVID-19 admitted to both intensive care units (ICUs) and medical wards (MWs). Consecutive patients admitted for COVID-19 to the MW and the ICU at Padua University Hospital, all receiving thromboprophylaxis, underwent systematic ultrasonography of the internal jugular, and the upper and lower limbs veins every 7 days (± 1 day) after the admission; and, if negative, once-weekly until discharge or death. In case of suspected pulmonary embolism, a multidetector computed tomographic angiography was performed. The primary outcome was the proportion of any deep-vein thrombosis (DVT) and symptomatic pulmonary embolism in both groups. An extended blood coagulative test was performed as well. From March 4 to April 30, 2020, a total of 85 patients were investigated, 44 (52%) in MWs and 41 (48%) in the ICU. Despite thromboprophylaxis, VTE occurred in 12 patients in the MWs (27.3%) and 31 patients in the ICU (75.6%) with an odds ratio of 9.3 (95% confidence interval (CI) 3.5-24.5; P < 0.001). Multiple-site DVT occurred in 55.6% of patients (95% CI 39.6-70.5). Increased D-dimer levels significantly correlated with VTE (P = 0.001) and death (P = 0.015). Summarizing, patients with COVID-19 admitted to the MW or ICU showed a high frequency of venous thromboembolism, despite standard-dose or high-dose thromboprophylaxis. Whether thrombosis, particularly asymptomatic events, may play a role in the morbidity and mortality of patients with COVID-19 remain to be clarified.
尽管进行了血栓预防,但患有 2019 年冠状病毒病(COVID-19)的患者表现出高凝状态和更高的静脉血栓栓塞风险,尽管其实际发病率尚不清楚。本研究的目的是评估入住帕多瓦大学医院的重症监护病房(ICU)和医疗病房(MW)的 COVID-19 患者的静脉血栓栓塞(VTE)发生率。所有接受血栓预防的 MW 和 ICU 连续收治的 COVID-19 患者,在入院后每 7 天(±1 天)进行一次颈内静脉、上下肢静脉的系统超声检查;如果阴性,则每周一次,直至出院或死亡。如果怀疑发生肺栓塞,则进行多层螺旋 CT 血管造影检查。主要结局是两组中任何深静脉血栓形成(DVT)和症状性肺栓塞的比例。还进行了扩展凝血试验。2020 年 3 月 4 日至 4 月 30 日,共对 85 例患者进行了调查,MW 中有 44 例(52%),ICU 中有 41 例(48%)。尽管进行了血栓预防,但 MW 中有 12 例(27.3%)和 ICU 中有 31 例(75.6%)患者发生 VTE,优势比为 9.3(95%置信区间(CI)3.5-24.5;P<0.001)。多处 DVT 发生在 55.6%的患者中(95%CI 39.6-70.5)。D-二聚体水平升高与 VTE(P=0.001)和死亡(P=0.015)显著相关。总之,入住 MW 或 ICU 的 COVID-19 患者尽管接受了标准剂量或高剂量的血栓预防,但静脉血栓栓塞的发生率仍然很高。血栓形成,特别是无症状事件,是否可能在 COVID-19 患者的发病率和死亡率中起作用,仍有待阐明。